FDA Expands Anktiva Label to Papillary-Only Bladder Cancer

ImmunityBio received an important label expansion for Anktiva, its bladder-cancer therapy used with Bacillus Calmette-Guérin, or BCG. The U.S. Food and Drug Administration added adults with BCG-unresponsive, papillary-only non-muscle-invasive bladder cancer to the approved population.

The change closes a gap in the original U.S. label. Anktiva was approved in April 2024 for carcinoma in situ, or CIS, with or without papillary tumors. Patients with papillary tumors but no CIS were not included. The expanded indication arrived before the January 6, 2027 target date assigned when the agency accepted ImmunityBio's supplemental application.

Papillary disease represents a large share of non-muscle-invasive bladder cancer, but the company's statement that it accounts for about 85% of the population should not be confused with the number of patients who meet every requirement of the new label. Eligible patients must still have BCG-unresponsive disease and satisfy clinical and prescribing criteria.

The evidence also needs careful attribution. The earlier QUILT-3.032 study in CIS patients reported a 62% complete-response rate among 77 evaluable patients, with 58% of responders maintaining a response for at least 12 months and 40% for at least 24 months. Those figures support the therapy's established CIS use; they are not direct response results from a separate randomized papillary-only trial.

According to ImmunityBio, the FDA considered the existing clinical evidence and similarities between CIS and papillary disease. That regulatory conclusion broadens commercial opportunity, but it does not remove execution questions around diagnosis, BCG availability, physician adoption, reimbursement and manufacturing.

For IBRX investors, the approval is a positive catalyst because it expands the label without waiting until the target action date. The next evidence should come from product revenue and adoption, not social-media sentiment. ImmunityBio reported $50.7 million of second-quarter 2026 net product revenue and $94.8 million for the first half. Investors now have a measurable base against which to judge whether the broader label changes the sales trajectory.